New Delhi: Aiming for a "fair share" of the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and increase localization while expanding the reach of its existing brands through collaboration with domestic pharmaceutical companies. , according to a top company official.
The company plans to expand its presence in the diabetes sector and grow the consumer healthcare business after spinning it off into a new entity, while also focusing on local production of its various best-in-class products in India.
Speaking with PTI, Sanofi India Managing Director Rodolfo Hroz said the company has launched a mission to prepare for an accelerated growth path in the country.
"We believe we are underrepresented (in India) and we see a significant opportunity now and in the future. The potential of this market is phenomenal," he said.
He further added, “We are looking for a way to have better representation with a fair share in the Indian pharmaceutical market.,
Describing India as a very important market for the company, Hroz said that the company sees immense growth potential in the country over the next few years.
He said diabetes is a big focus area for the company. "Diabetes is an unsolved problem in India. Continuing to advance diabetes care in India is one of Sanofi's priorities," he said.
With Solica, the company will enter the premix insulin segment, providing physicians with more customized options for better diabetes management. Hroz said.He said, the company realizes that there are many global best-in-class products that can be brought to the Indian market and offered to healthcare professionals and patients in India.
Hroz said Sanofi has a pipeline of 12 different products for launch in the country.
Apart from Solika (pre-mixed insulin), the company plans to launch Dupixent, the first biologic drug for the treatment of moderate to severe atopy dermatitis in adults in the country.
Other products in the pipeline include Xenpozyme, Nexviazyme, Befortus and Razurock, Hroz said. "So we have a very strong pipeline of products for the Indian market over the next few years," he said.
Hroz said the company works with 15 contract manufacturing organizations in the country.It also has its own manufacturing footprint in Goa.
“We have a very strong production base in India and we want to continue to explore and leverage that,” he said.
Sanofi Healthcare India has recently tied up with companies like Cipla, Dr. Reddy's Laboratories and Emcure to expand the reach of its products in the country.
"So it's a clear strategy in terms of maximizing the reach of existing products," Hroz said.
The company plans to expand its presence in the diabetes sector and grow the consumer healthcare business after spinning it off into a new entity, while also focusing on local production of its various best-in-class products in India.
Speaking with PTI, Sanofi India Managing Director Rodolfo Hroz said the company has launched a mission to prepare for an accelerated growth path in the country.
"We believe we are underrepresented (in India) and we see a significant opportunity now and in the future. The potential of this market is phenomenal," he said.
He further added, “We are looking for a way to have better representation with a fair share in the Indian pharmaceutical market.,
Describing India as a very important market for the company, Hroz said that the company sees immense growth potential in the country over the next few years.
He said diabetes is a big focus area for the company. "Diabetes is an unsolved problem in India. Continuing to advance diabetes care in India is one of Sanofi's priorities," he said.
With Solica, the company will enter the premix insulin segment, providing physicians with more customized options for better diabetes management. Hroz said.He said, the company realizes that there are many global best-in-class products that can be brought to the Indian market and offered to healthcare professionals and patients in India.
Hroz said Sanofi has a pipeline of 12 different products for launch in the country.
Apart from Solika (pre-mixed insulin), the company plans to launch Dupixent, the first biologic drug for the treatment of moderate to severe atopy dermatitis in adults in the country.
Other products in the pipeline include Xenpozyme, Nexviazyme, Befortus and Razurock, Hroz said. "So we have a very strong pipeline of products for the Indian market over the next few years," he said.
Hroz said the company works with 15 contract manufacturing organizations in the country.It also has its own manufacturing footprint in Goa.
“We have a very strong production base in India and we want to continue to explore and leverage that,” he said.
Sanofi Healthcare India has recently tied up with companies like Cipla, Dr. Reddy's Laboratories and Emcure to expand the reach of its products in the country.
"So it's a clear strategy in terms of maximizing the reach of existing products," Hroz said.
